Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

Introduction At present, there are some differences in the research results of molnupiravir.
The purpose of this study was to evaluate the efficacy and safety of molnupiravir in the …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the
end of 2019 stimulated vigorous research efforts in immunology and vaccinology. In addition …

Purpose Preliminary evidence suggests a potential effect of antiviral medication used during
the acute COVID-19 phase for preventing long-COVID. This review investigates if having …

The presence of symptoms after an acute SARS-CoV-2 infection (long-COVID) has become
a worldwide healthcare emergency but remains underestimated and undertreated due to a …

Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge
Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge J Med …

Introduction Azivudine has undergone a few randomized controlled trials (RCTs) as of late.
This study aimed to assess the COVID-19 treatment with azvudine's efficacy and safety …

Introduction At present, there are some randomized controlled trials (RCTs) of oral small
molecule drugs. The purpose of this study was to evaluate the efficacy and safety of oral …

Objectives A reappraisal of the validity of the conclusions of systematic reviews (SRs)
related to nirmatrelvir/ritonavir for the treatment of COVID-19. Methods An overview of SRs …

Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-
moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high …